Skip to main content

Table 5 Five- and 10-year cumulative incidence of loco-regional recurrence of breast cancer patients with local R0 resection by age, tumor characteristics and provided recommended treatments

From: Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

Category/treatment

 

N

5-year CI

10-year CI

p-value

 

PE

95% CI

PE

95% CI

 

Overall

 

5311

5.4

[4.8, 6.0]

7.8

[7.0, 8.6]

 

Age

<  70 years

3714

5.7

[5.0, 6.5]

8.5

[7.6, 9.5]

0.007

 

≥ 70 years

1597

4.5

[3.6, 5.6]

6.1

[4.9, 7.4]

Clinical stage

T1/2N0

2918

2.8

[2.3, 3.5]

5.1

[4.3, 6.1]

< 0.001

 

T1/2N+

1613

7.3

[6.1, 8.7]

10.3

[8.8, 12.0]

T3/4N0

124

8.9

[5.0, 15.7]

13.0

[8.0, 21.1]

T3/4N+

409

13.9

[10.9, 17.7]

15.1

[12.0, 19.0]

missing

247

6.9

[4.4, 11.0]

7.8

[5.1, 12.1]

Morphology

invasive ductal

3690

5.7

[5.0, 6.5]

8.1

[7.2, 9.1]

0.395

 

invasive lobular

758

4.5

[3.2, 6.3]

8.0

[6.2, 10.5]

mixed type

459

4.1

[2.7, 6.4]

6.0

[4.1, 8.7]

other

404

5.5

[3.7, 8.3]

6.5

[4.4, 9.5]

Histopathologic grade

1

447

1.3

[0.6, 3.0]

3.3

[1.9, 5.9]

< 0.001

 

2

3332

4.3

[3.6, 5.0]

6.6

[5.8, 7.6]

3/4

1497

8.8

[7.5, 10.3]

11.4

[9.9, 13.3]

missing

35

11.4

[4.5, 29.2]

15.5

[6.7, 36.0]

HR expression

positivea

4132

4.1

[3.6, 4.8]

6.6

[5.8, 7.4]

< 0.001

 

negative

775

12.4

[10.3, 15.0]

15.2

[12.8, 18.1]

missing

404

4.2

[2.7, 6.8]

5.2

[3.4, 8.0]

HER2/neu expression

positiveb

972

7.1

[5.7, 8.9]

10.8

[8.8, 13.2]

0.004

 

negative

2941

4.9

[4.2, 5.7]

6.9

[6.0, 8.0]

missing

1398

5.1

[4.1, 6.4]

7.6

[6.3, 9.2]

Subtype based on immunohistochemical surrogates

‘HR positive‘

4132

4.1

[3.6, 4.8]

6.6

[5.8, 7.4]

< 0.001

 

‚HER2/neu positive‘c

234

12.9

[9.2, 18.0]

16.2

[11.8, 22.3]

‘triple negative‘d

376

12.0

[9.1, 15.8]

13.8

[10.6, 17.9]

missing

569

6.7

[4.9, 9.1]

9.1

[6.9, 11.9]

BCS

T1/2N0

198

3.6

[1.7, 7.4]

4.9

[2.3, 10.2]

BCS + RT

T1/2N0

2114

2.1

[1.6, 2.9]

4.4

[3.5, 5.5]

Mastectomy

T1/2N0

606

4.8

[3.4, 6.9]

7.9

[5.9, 10.5]

(BCS + RT or mastectomy) + HT

T1/2N0 HR positive a

1749

1.7

[1.2, 2.4]

4.3

[3.3, 5.5]

(BCS + RT or mastectomy) + CT

T1/2N0 HR negative

277

6.5

[4.2, 10.2]

9.3

[6.3, 13.7]

(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT

T1/2N0 HER2/neu positive

73

0.0

0.0

(BCS or mastectomy) + RT + CT + HT

T1/2N+ HR positive a

554

5.8

[4.2, 8.2]

8.3

[6.2, 11.2]

(BCS or mastectomy) + RT + CT

T1/2N+ HR negative

156

12.9

[8.5, 19.4]

16.5

[11.3, 24.1]

(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT

T1/2N+ HER2/neu positive

51

9.8

[4.2, 22,7]

9.8

[4.2, 22,7]

MAST + RT + CT + HT

T3/4 HR positive a

88

17.0

[10.7, 27.1]

17.0

[10.7, 27.1]

MAST + RT + CT

T3/4 HR negative

50

22.0

[13.0, 37.3]

26.2

[16.3, 42.1]

  1. The sample includes female patients with primary invasive breast cancer (ICD-10 code: C50) without distant metastases from Saarland diagnosed between 1999 and 2009. CI cumulative incidence, PE point estimate of CI, 95% CI 95% confidence interval of PE, T, N T and N category of TNM classification, HR hormone receptor, HER2/neu human epidermal growth factor receptor 2, BCS breast conserving surgery, RT radiotherapy, CT chemotherapy, HT hormonal (anti-estrogen) treatment, TT targeted treatment (trastuzumab). aincludes tumors with mixed HR expression (either estrogen or progesterone receptor positive), bincludes tumors with borderline expression of HER2/neu, cHER2/neu positive, but HR negative, dboth HR negative and HER2/neu negative